Deborah McElhone, head of sustainability pharma at the Centre for Process Innovation (CPI), discusses the partnership between India and the UK. The UK’s National Health Service (NHS) is targeting net zero with its Scope1, 2 and 3 emissions by 2045. Given the global nature of pharmaceutical supply chains and the fact that 25% of medicines dispensed in the UK are sourced from India, addressing this target requires collaborative efforts on a worldwide scale.  Although India has set ambitious sustainability targets, including commitments to achieve net zero emissions by 2070, these targets do not fully align with NHS ambitions, potentially leading…

Christy Eatmon, global subject matter expert, steriles, Thermo Fisher Scientific explores how to meet the growing demand for prefilled syringes. The pharmaceutical industry has always been resolutely focused on getting safe and effective therapies to patients in need and, with that, meeting a growing demand for therapeutics that are also easy to administer. Healthcare providers and patients alike are seeking more convenient methods to gain the positive outcomes experienced with medications historically delivered via less patient-friendly technologies, particularly those that require very frequent dosage or professional administration. Enabled by technological advancements, innovative drug delivery devices – such as prefilled syringes…

Mario Toubes-Rodrigo, global applications leader, H.E.L Group shares how high pressure bioreactors can transform fermentation for a sustainable tomorrow. The history of using bioreactors for fermentation processes stretches back over 10,000 years, when pottery vessels were used to ferment a mixture of rice, honey, and fruit in China, but it was not until the 1950s that we started to see their use in pharma and biotech. Nowadays, bioprocessing plays a critical role in these industries, with emerging trends such as using sustainable feedstocks and waste byproducts to manufacture valuable and renewable products offering a novel approach to solving global challenges…

Niklas Adamsson, COO at Envirotainer looks at the key considerations when preparing the cold chain for climate change. Global distribution of life-saving pharmaceuticals is incredibly complex, with several different components from warehouse to final delivery. At each stage, providers must make sure strict temperature requirements are met across varying climates and infrastructures.  Here are some key considerations when preparing the cold chain for climate change.  1. Cold chains need to be smarter and stronger  One key consideration is that as weather becomes increasingly volatile, cold chains need to become smarter and stronger. Supply chain disruptions can easily cause issues with…

Aaron Quinn, senior manager – Europe, Vantage Nutrition highlights how V-beads technology is redefining supplement delivery. In recent years, the conversation around nutraceuticals has moved far beyond ingredient lists and recommended daily intakes. Today’s consumer is no longer satisfied with knowing what’s in it, they’re asking how it’s delivered. The delivery system is becoming the critical differentiator in a market increasingly driven by efficacy, bioavailability, and transparency.  Among the emerging solutions, beadlet technology—and specifically V-beads—is redefining intelligent supplementation. By optimising how active ingredients are protected, released, and absorbed, V-beads signal a fundamental shift in how the nutraceutical industry approaches formulation. …

Bionova Scientific, a contract development and manufacturing organisation (CDMO), is entering the advanced therapy manufacturing space. The company is installing its third FlexFactory manufacturing platform from Cytiva, a Danaher company, to help meet the surging demand for advanced therapies, while maintaining their core monoclonal antibody (mAb) business. Bionova will also use Cytiva’s Fast Trak process development services to help advance their entry into genomic medicines. Fabio Fonseca, Ph.D. senior director, pDNA Process Development, Bionova Scientific, said: “Using Cytiva’s end-to-end solutions, we’ll have an exceptional platform to support the manufacture of genomic medicines. Together with our team and technology stack, we are…

Nigel Theobald, CEO, N4 Pharma explores the future of targeted therapeutics with next-generation silica nanoparticle delivery. In the evolving landscape of precision medicine and targeted therapy, success is increasingly determined not only by the efficacy of the drug itself, but also on the precision and reliability of the delivery mechanism employed. Targeted therapeutics, designed to interact with specific cellular pathways or disease sites, necessitate delivery systems that can evade the natural defences and barriers within the body to reach their intended targets without eliciting adverse effects.  The demand for delivery technologies that can safely, precisely and efficiently transport RNA therapeutics…

PCI Pharma Services will use the BIO International Convention, 16-19th June in Boston, as a platform to introduce its new purpose-built facility for large-scale sterile fill-finish operations at its campus in nearby Bedford, NH. At Booth 1979, PCI experts will provide attendees with key updates as the 50,000-square-foot facility approaches full-scale GMP production this summer.    With site construction and infrastructure installation now complete, PCI has commenced qualification activities for the Bedford plant’s Annex 1-compliant sterile fill-finish manufacturing technologies. Among other highlights, the facility houses an aseptic vial fill-finish line within a fully isolated containment system, equipped with twin 430-sq-ft lyophilisers…

IMA has created two new centres of expertise within the organisation: the IMA AI LAB and Embedded Data Machines. Their mission is to consolidate and expand the use of AI across several fronts – from integrating intelligent functionalities into machines and plants, to advanced data collection and analysis, to the development of predictive algorithms and advanced tools for support and technical assistance. Special focus will be given to enhancing advanced troubleshooting through intelligent systems capable of anticipating, diagnosing, and resolving anomalies with increasing speed and precision.  This further development and implementation of AI stems from the consolidation and structuring of…

Aragen, a contract research, development and manufacturing organisation (CRDMO), announced that it will commence GMP manufacturing at its biologics manufacturing facility in Bangalore, India from late July 2025.  Aragen has successfully completed the facility and equipment qualification and demonstrated the productivity of its intensified fed batch cell culture manufacturing platform to deliver titers >25 g/L.  The news, released ahead of BIO Boston, comes on the back of several successful pharma customer audits with more biotech discussions expected to accelerate at the event.  The facility opens with the flexibility to house multiple 2KL Single use Bioreactors, set up for both fed…

Despite its growing threat to global health, research aimed at tackling antimicrobial resistance (AMR) has been constrained for many years, most likely due to the rapid evolution of resistance in pathogens, regulatory and policy barriers, and high research and development (R&D) costs. However, recent developments have led to a growing belief that viable solutions to this pressing global health issue may be within reach. Georgia Mann, senior associate, Withers & Rogers discusses.  The World Health Organisation (WHO) has identified AMR as one of the most serious global health threats. In 2019 alone, bacterial AMR directly caused an estimated 1.27 million deaths and was associated…

Human Data Sciences (HDS), the UK-based medtech company behind the real-world data analytics platform Livingstone, has launched a landmark update to the platform that enables researchers to conduct comparative outcomes studies across multiple endpoints simultaneously. This new capability arrives at a critical time for the life sciences industry, particularly in Europe, where the implementation of the EU Joint Clinical Assessment Regulation (EU HTA) is creating increased demand for rapid comparative effectiveness data to support regulatory decisions. This comparative outcome study update offers a rapid, automated, and scientifically rigorous solution for generating comparative evidence at scale.  “This update introduces a step-change in how comparative outcomes…

Russell Miller, VP, global sales and marketing, Enzene shares how to drive down the cost of monoclonal antibody manufacturing. Monoclonal antibodies (mAbs) have become central to modern biopharmaceutical therapy, with clinical applications spanning oncology, autoimmune diseases, and infectious disorders. Yet despite their clinical significance, mAbs remain expensive to manufacture, posing a persistent barrier to affordability and access, particularly in resource-limited settings.  With biotech companies still struggling to secure funding and capital markets remaining tight, there is a growing imperative to stretch resources and reduce the cost of this promising modality. Rising manufacturing costs, compounded by economic uncertainty and pricing pressures,…

Verista, a provider of automation, compliance, and quality solutions for the pharmaceutical industry, highlights the LABELQ Label & Print Reconciliation System, a platform engineered to transform label management for medical device, pharmaceutical, and contract manufacturers.  LABELQ streamlines operations by integrating print, inspection, and accountability into a single, unified platform, significantly increasing efficiency and reducing operational complexity for small and medium batch production environments.  LABELQ is designed to deliver 100% automatic label inspection with real-time feedback. This inspection capability reduces the risk of product recalls, label mix-ups, and poor label quality, safeguarding both brand reputation and end-customer trust. By automating record…

Olivia Friett recently had the opportunity to attend i-team Global’s immersive launch, in Dublin, of the SAFE-T-product family – a suite of battery-powered floor cleaning solutions designed for cleanrooms. European Pharmaceutical Manufacturer spoke to Ryan McClymonds, global technical director about cleanroom challenges and how these products help to tackle them.  What specific cleanroom challenges do you aim to address with the new SAFE-T range?   The biggest challenge for keeping cleanrooms hygienically clean is labour and time. In the pharmaceutical sector, including in laboratories where stringent contamination control is needed, floor cleaning has relied heavily on manual wiping and mopping. I’ve seen this…

Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates, has announced a manufacturing partnership with Sterling Pharma Solutions, a global contract development and manufacturing organisation (CDMO), to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology antibody-drug conjugate (ADC) candidate, KIVU-107.  Under the agreement, Sterling will manufacture cGMP clinical material for KIVU-107 at its dedicated bioconjugation facility in Deeside, UK. The collaboration includes process familiarisation, analytical development, process optimisation, and scale-up activities in preparation for a cGMP manufacturing campaign.  “We chose Sterling as our manufacturing partner based on their deep expertise in ADC development, proven track record of…

As we move further into 2025, it’s clear the pharmaceutical manufacturing sector is at a pivotal point. We’re seeing real momentum, in the industry – but also a lot of pressure. Olivia Friett, editor of European Pharmaceutical Manufacturer discusses. COVID-19 exposed just how fragile global supply chains can be, particularly when it comes to sourcing APIs and essential raw materials. In the years since, we’ve seen a clear effort to strengthen local manufacturing and reduce dependence on external suppliers. This hasn’t been an easy journey. It’s about building long-term security, boosting innovation, and ensuring the industry can respond quickly in…

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has announced an international collaboration with Thermo Fisher Scientific.  The collaboration will combine Thermo Fisher’s proven cell culture and processing technology and Cellular Origins’ CGT robotic manufacturing platform, Constellation, to deliver full, robotic, 24/7 production of CGTs to the advanced therapy sector at the industrial scale. Both companies aim to achieve the largest production output of CGTs per square metre of manufacturing space, as well as the lowest labour requirements currently available within a digitally integrated framework. The primary aim of the…

The pharmaceutical industry faces significant challenges in its mission to provide safe, effective, and affordable products. Noam Nahari, VP marketing & business development at LOG Pharma Primary Packaging discusses. Achieving this goal is particularly demanding for suppliers to the drug industry, which must consistently meet stringent standards while controlling costs.  Amid this reality, the R&D team at LOG Pharma Primary Packaging, which has been developing innovative packaging solutions for the international pharmaceutical and medical sectors for more than 50 years, was presented with a formidable task several years ago. Pushing boundaries, management asked the team to develop a packaging solution…

Shilpa Biocare, a fully-owned subsidiary of Shilpa Medicare, announces ahead of BIO Boston that it has secured a Europe-wide commercial supply agreement with Orion Corporation for Recombinant Human Albumin. Shilpa’s Recombinant Human Albumin – a key plasma protein used in various therapeutic applications – is currently under development and will be manufactured using a robust non-human expression system. This provides improved safety, scalability, and virus-free production, addressing some of the key limitations associated with human-derived albumin. Under the terms of the agreement, Orion will gain exclusive rights to distribute, market and sell Shilpa’s Recombinant Human Albumin in Europe, with Shilpa receiving development and…

European Pharmaceutical Manufacturer talks to leading companies to see what’s happening at BIO Boston. Hongene – David Butler, CTO  What are you most looking forward to?  At BIO Boston, we’re most looking forward to connecting with partners across the nucleic acid therapeutics ecosystem who share our commitment to advancing the next generation of RNA and oligonucleotide-based medicines. This event offers a unique opportunity to engage with innovators tackling the complexities of nucleic acid manufacturing and to explore collaborations that help accelerate the transition from concept to clinic.  We’re especially eager to discuss how emerging manufacturing methodologies and integrated CDMO capabilities can…

XL-protein has announced that it has entered into a worldwide License, Development and Commercialisation Agreement with Grifols for a long-acting biopharmaceutical product. Under this collaboration, XL-protein will leverage its proprietary, clinical-stage PASylation technology to extend the circulation of Grifols therapeutics, paving the way for a more effective and long-lasting treatment. XL-protein will actively support preclinical development activities while Grifols will be entitled to further developing as well as manufacturing and marketing the PASylated-enhanced biologic. Under the terms of the agreement, XL-protein will receive an upfront payment as well as payments for achievement of preclinical, clinical, regulatory and commercial milestones. Furthermore, XL-protein…

Watson-Marlow Fluid Technology Solutions (WMFTS) has introduced WMArchitect Interchangeable Parts to secure a resilient supply of single-use assemblies by including pre-qualified, alternative components in the design stage to avoid regulatory compliance interruptions and long lead times.   The new service for bioprocessing eliminates the disruption of reduced component stock and potential production shutdowns, to instead enable a simplified way to substitute in suitable components with shorter lead times.   Interchangeable Parts provides qualified, alternative component options in an assembly which are agreed during the design stage. This avoids supply constraints of a specific component, such as tubing, tri-clamps and other tube fittings.  Alongside…